Details of Disease

General Information of Disease (ID: DISBKFB7)

Disease Name	Brain cancer
Synonyms	primary brain tumour; primary brain tumor; primary brain neoplasm; neoplasm of unspecified nature of brain; brain tumor, adult; brain neoplasm, adult; BT - brain tumour; BT - brain tumor; malignant tumour of adult brain; malignant tumor of adult brain; malignant primary brain tumour; malignant primary brain tumor; malignant primary brain neoplasm; adult malignant brain neoplasm; adult brain tumour; adult brain tumor; tumour of the brain; tumor of the brain; brain neoplasm; primary malignant neoplasm of brain; malignant tumour of the brain; malignant tumour of brain; malignant tumor of the brain; malignant tumor of brain; malignant neoplasm of the brain; malignant neoplasm of brain; malignant brain tumour; malignant brain tumor; malignant brain neoplasm; cancer of the brain; cancer of brain; brain neoplasms, malignant; brain cancer
Disease Class	2A00: Brain cancer
Definition	A primary or metastatic malignant neoplasm affecting the brain.
Disease Hierarchy	DISNVYSW: Central nervous system cancer DISAT1Z9: Advanced cancer DISOFCZS: Malignant primary brain tumour DISBKFB7: Brain cancer
ICD Code	ICD-11 ICD-11: 2A00 Expand ICD-11 '2A00 Expand ICD-9 191225
Disease Identifiers	MONDO ID MONDO_0001657 MESH ID D001932 UMLS CUI C0153633 MedGen ID 57796 SNOMED CT ID 428061005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Borocaptate sodium B 10	DMUI9ST	Approved	NA	[1]
DTI-015	DMXZRW0	Approved	Small molecular drug	[2]
Erlotinib	DMCMBHA	Approved	Small molecular drug	[3]
Lomustine	DMMWSUL	Approved	Small molecular drug	[4]
Motexafin gadolinium	DMEJKRF	Approved	Small molecular drug	[5]
Prinomastat	DM9HOKG	Approved	Small molecular drug	[6]
Zinostatin stimalamer	DMK4OL7	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This Disease is Treated as An Indication in 29 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cintredekin besudotox	DMZNGJL	Phase 3	NA	[7]
DCVax-Brain	DMBXKI2	Phase 3	NA	[8]
DCVax-Ovarian	DMBLASN	Phase 3	NA	[9]
GliAtak	DMUEDFT	Phase 3	NA	[10]
ICT-107	DMBIZ7H	Phase 3	Vaccine	[9]
INO-1001	DM5L8QT	Phase 3	Small molecular drug	[11]
Rindopepimut	DMP6IMQ	Phase 3	NA	[12]
SOT-107	DMOFNVP	Phase 3	NA	[13]
NLG8189	DM0798Z	Phase 2/3	Small molecular drug	[14]
ABT-414	DMGUTPN	Phase 2	Antibody	[15]
APX005M	DMX2P5G	Phase 2	Antibody	[14]
CLR1404-I-124	DMIAEGX	Phase 2	NA	[16]
DM-CHOC-PEN	DMBC7HZ	Phase 2	NA	[17]
DNX-2401	DMDQ3XP	Phase 2	Oncolytic virus therapy	[18]
F18-ML-10	DM8HFRP	Phase 2	NA	[19]
Fresolimumab	DMFZ084	Phase 2	Antibody	[20]
L-alanosine	DMSIGAB	Phase 2	Small molecular drug	[21]
PDT with Photofrin	DMR9H2B	Phase 2	NA	[14]
PT2385	DMCSN69	Phase 2	NA	[22]
TVI-Brain-1 cancer vaccine	DM776EU	Phase 2	NA	[23]
Anti-EGFRvIII CAR transduced PBL	DMDKTYU	Phase 1/2	CAR T Cell Therapy	[24]
WP-1066	DMUGHWR	Phase 1/2	Small molecular drug	[23]
8H9	DMQ789Z	Phase 1	Antibody	[25]
Anti-CD133-CAR vector-transduced T cells	DMGUM90	Phase 1	CAR T Cell Therapy	[26]
CC-8490	DMXUT3Z	Phase 1	NA	[27]
DA-3607	DM4JG0B	Phase 1	NA	[28]
DC/I540/KLH vaccine	DM6K47B	Phase 1	Vaccine	[29]
KX2-361	DML4H05	Phase 1	NA	[30]
MR1-1	DME7JFM	Phase 1	NA	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 29 Drug(s)

This Disease is Treated as An Indication in 7 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ranagengliotucel-T	DMNTURD	Discontinued in Phase 3	Vaccine	[32]
Sitimagene ceradenovec	DM0T2QV	Discontinued in Phase 3	NA	[33]
Labradimil	DMSFL76	Discontinued in Phase 2	Small molecular drug	[34]
Brain tumor vaccine	DM9HV1N	Discontinued in Phase 1	NA	[35]
131I-81C6	DMVO0LU	Terminated	Antibody	[36]
NSD-551	DMGYTPB	Terminated	NA	[37]
PCNU	DM98MSW	Terminated	Small molecular drug	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AGT-2000	DMP9QW0	Investigative	NA	[39]
EDP-19	DMEA73A	Investigative	NA	[40]
MIQ-004	DMJI5OH	Investigative	NA	[40]
NV.XOD.09	DMDT9IU	Investigative	NA	[40]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 38 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BRAF	TT0EOB8	Limited	Genetic Variation	[41]
CYP2C9	TTR40YJ	Limited	Biomarker	[42]
LGR5	TTTSGRH	Limited	Biomarker	[43]
SPP1	TT8ME6I	Limited	Biomarker	[44]
PTEN	TTXJ3W7	moderate	Genetic Variation	[45]
SMO	TT8J1S3	moderate	Biomarker	[46]
ADAM8	TTQWYMD	Strong	Biomarker	[47]
ALK	TTPMQSO	Strong	Biomarker	[48]
AMOT	TTI48OS	Strong	Biomarker	[49]
BRDT	TT7CPI5	Strong	Biomarker	[50]
BST2	TT90BJT	Strong	Biomarker	[51]
CCND1	TTFCJ7S	Strong	Biomarker	[49]
CSNK1D	TTH30UI	Strong	Biomarker	[52]
DLL1	TT9CFQD	Strong	Biomarker	[53]
DYRK1A	TTSBVFO	Strong	Altered Expression	[54]
EML4	TT92GY4	Strong	Biomarker	[48]
FDPS	TTIKWV4	Strong	Altered Expression	[55]
GLIPR1	TTEQF1O	Strong	Biomarker	[56]
IDH1	TTV2A1R	Strong	Biomarker	[57]
IMPDH2	TTTB4UP	Strong	Altered Expression	[58]
ITGB2	TTIJWR7	Strong	Biomarker	[49]
MGMT	TTJ8DV7	Strong	Biomarker	[59]
PCNA	TTLG1PD	Strong	Biomarker	[60]
PDGFD	TTSN0GA	Strong	Altered Expression	[61]
PON1	TT9LX82	Strong	Biomarker	[62]
RTN4R	TTVRZUO	Strong	Altered Expression	[63]
S100B	TTQ0V86	Strong	Biomarker	[49]
SMYD2	TT7YJFO	Strong	Biomarker	[64]
SULF2	TTLQTHB	Strong	Biomarker	[65]
TGFBR2	TTZE3P7	Strong	Biomarker	[49]
TNFRSF12A	TTKPS7V	Strong	Altered Expression	[66]
YAP1	TT8UN2D	Strong	Biomarker	[49]
CDK4	TT0PG8F	Definitive	Biomarker	[67]
CDKN2A	TTFTWQ8	Definitive	Biomarker	[68]
EGFR	TTGKNB4	Definitive	Altered Expression	[69]
IL2	TTF89GD	Definitive	Biomarker	[70]
SIRT1	TTUF2HO	Definitive	Biomarker	[71]
TGM2	TT2F4OL	Definitive	Therapeutic	[72]
------------------------------------------------------------------------------------


⏷ Show the Full List of 38 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCA2	DTJ4NEG	Strong	Biomarker	[73]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HK1	DEDMAGE	Limited	Biomarker	[74]
------------------------------------------------------------------------------------

This Disease Is Related to 59 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAM23	OTVWT6JZ	Limited	Genetic Variation	[75]
L3MBTL1	OT8M52QY	Limited	Genetic Variation	[76]
L3MBTL2	OTKX1XIX	Limited	Biomarker	[77]
MBTD1	OT2P6943	Limited	Biomarker	[78]
MGAT5B	OT5HP73K	Limited	Biomarker	[79]
OLIG2	OTMCN6D3	Limited	Altered Expression	[80]
SPTLC1	OTN0Z98K	Limited	Biomarker	[81]
PTCH1	OTMG07H5	moderate	Biomarker	[46]
ACSM3	OT0AE1IV	Strong	Biomarker	[82]
ADGRE2	OTUYJVYG	Strong	Biomarker	[83]
ADGRE5	OTTSB84Q	Strong	Biomarker	[83]
ALDH1A3	OT1C9NKQ	Strong	Biomarker	[84]
BCCIP	OTFFKG79	Strong	Biomarker	[85]
BIRC6	OTCQJAB0	Strong	Altered Expression	[86]
BRMS1L	OTJIW47U	Strong	Altered Expression	[87]
C10orf67	OTX24W0H	Strong	Genetic Variation	[88]
CAPZB	OTF1A4N0	Strong	Genetic Variation	[89]
CD8A	OTDWQJXK	Strong	Altered Expression	[90]
DAPK1	OTNCNUCO	Strong	Biomarker	[91]
DTX2	OT7QLDU4	Strong	Biomarker	[53]
EHD3	OTOKC2G5	Strong	Altered Expression	[92]
EXTL3	OT2BRUBN	Strong	Biomarker	[93]
EZHIP	OTDP2O9X	Strong	Genetic Variation	[88]
FABP7	OTRE2H4G	Strong	Biomarker	[94]
FJX1	OT8SVTSS	Strong	Biomarker	[49]
HES5	OTW7JEHV	Strong	Biomarker	[53]
ING2	OT6H0EWF	Strong	Altered Expression	[90]
IQGAP1	OTZRWTGA	Strong	Biomarker	[49]
IQGAP2	OTX2UA7P	Strong	Biomarker	[49]
LGI1	OTPS77HO	Strong	Genetic Variation	[95]
NLGN3	OTKDEC1Q	Strong	Altered Expression	[96]
NRARP	OTMYHUV2	Strong	Biomarker	[53]
NRF1	OTOXWNV8	Strong	Altered Expression	[97]
NT5C3A	OT67KZJA	Strong	Genetic Variation	[89]
OTX2	OTTV05B1	Strong	Altered Expression	[98]
PDC	OT1UUVYY	Strong	Biomarker	[99]
PDCD10	OTCHJTSF	Strong	Genetic Variation	[100]
PDP1	OT82RTMT	Strong	Altered Expression	[101]
PHF20L1	OTCLYOCL	Strong	Biomarker	[102]
PHLDA2	OTMV9DPP	Strong	Altered Expression	[103]
PLK5	OTW5YPKM	Strong	Altered Expression	[104]
PPP2R2C	OTXK0SDM	Strong	Biomarker	[105]
PRB2	OTAD4JZ0	Strong	Altered Expression	[106]
RALGDS	OTG36NI7	Strong	Genetic Variation	[107]
RBBP4	OTG3BT3M	Strong	Biomarker	[108]
RELA	OTUJP9CN	Strong	Biomarker	[60]
RHBDD1	OTL5J132	Strong	Biomarker	[109]
RPS15A	OT0BUA12	Strong	Altered Expression	[110]
SDCBP	OTS3NCC5	Strong	Biomarker	[111]
SERPINI1	OTUJHIJW	Strong	Altered Expression	[100]
SFMBT1	OTKMZIBW	Strong	Biomarker	[112]
SMG8	OTY9PCZY	Strong	Biomarker	[73]
SPRY4	OT2VK9N0	Strong	Altered Expression	[113]
STATH	OTQHBHM9	Strong	Genetic Variation	[114]
SULF1	OTJCNCO0	Strong	Altered Expression	[65]
TCF12	OTZVONNU	Strong	Biomarker	[115]
TMEFF1	OTH6M3CH	Strong	Biomarker	[116]
TPSG1	OTDESHKT	Strong	Genetic Variation	[117]
TRADD	OTBOSJHO	Strong	Altered Expression	[118]
------------------------------------------------------------------------------------


⏷ Show the Full List of 59 DOT(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
3	Erlotinib FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7214).
5	Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv. 2002 Nov;57(3):387-94.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505).
7	ClinicalTrials.gov (NCT00076986) The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme. U.S. National Institutes of Health.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017222)
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	ClinicalTrials.gov (NCT01436968) Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer. U.S. National Institutes of Health.
11	Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
12	ClinicalTrials.gov (NCT01480479) Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma. U.S. National Institutes of Health.
13	ClinicalTrials.gov (NCT00088400) Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors. U.S. National Institutes of Health.
14	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034046)
17	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029242)
18	ClinicalTrials.gov (NCT02798406) Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). U.S. National Institutes of Health.
19	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037619)
20	ClinicalTrials.gov (NCT01472731) Safety and Imaging Study of GC1008 in Glioma. U.S. National Institutes of Health.
21	ClinicalTrials.gov (NCT00062283) Alanosine in Treating Patients With Cancer. U.S. National Institutes of Health.
22	Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236.
23	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24	ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
25	ClinicalTrials.gov (NCT01502917) Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy. U.S. National Institutes of Health.
26	ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
27	ClinicalTrials.gov (NCT00074646) Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas. U.S. National Institutes of Health.
28	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026657)
29	Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leu... Blood. 2006 Oct 15;108(8):2662-8.
30	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041844)
31	ClinicalTrials.gov (NCT01009866) Study of Immunotoxin, MR1-1. U.S. National Institutes of Health.
32	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210)
33	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015264)
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 672).
35	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007949)
36	Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502.
37	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019960)
38	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000870)
39	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
40	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
41	Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.J Neurosurg. 2019 Nov 1;133(6):1704-1709. doi: 10.3171/2019.8.JNS19643.
42	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
43	Knockdown of LGR5 suppresses the proliferation of glioma cells in vitro and in vivo.Oncol Rep. 2014 Jan;31(1):41-9. doi: 10.3892/or.2013.2826. Epub 2013 Oct 31.
44	Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea.Am J Pathol. 2006 May;168(5):1676-85. doi: 10.2353/ajpath.2006.050400.
45	Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization.Oncogene. 2017 Jun 29;36(26):3673-3685. doi: 10.1038/onc.2016.493. Epub 2017 Mar 6.
46	Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.Cancer Res. 1998 May 1;58(9):1798-803.
47	ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance.Clin Sci (Lond). 2019 Jan 11;133(1):83-99. doi: 10.1042/CS20180906. Print 2019 Jan 15.
48	Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?.Cancer Biol Ther. 2012 Dec;13(14):1376-83. doi: 10.4161/cbt.22255. Epub 2012 Sep 17.
49	A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.Dis Model Mech. 2017 Jan 1;10(1):15-28. doi: 10.1242/dmm.026500. Epub 2016 Nov 24.
50	Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5086-E5095. doi: 10.1073/pnas.1712363115. Epub 2018 May 15.
51	The expression of BST2 in human and experimental mouse brain tumors.Exp Mol Pathol. 2011 Aug;91(1):440-6. doi: 10.1016/j.yexmp.2011.04.012. Epub 2011 May 1.
52	Development of dual casein kinase 1/1 (CK1/) inhibitors for treatment of breast cancer.Bioorg Med Chem. 2018 Feb 1;26(3):590-602. doi: 10.1016/j.bmc.2017.12.020. Epub 2017 Dec 15.
53	Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.Genes Cancer. 2010 Aug;1(8):822-35. doi: 10.1177/1947601910383564.
54	DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.Pharmacol Ther. 2015 Jul;151:87-98. doi: 10.1016/j.pharmthera.2015.03.004. Epub 2015 Mar 17.
55	The isoprenoid derivative N(6) -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway.Br J Pharmacol. 2017 Jul;174(14):2287-2301. doi: 10.1111/bph.13824. Epub 2017 Jun 11.
56	RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer.Cancer Res. 2004 Feb 1;64(3):969-76. doi: 10.1158/0008-5472.can-03-2592.
57	Single cell coagulomes as constituents of the oncogene-driven coagulant phenotype in brain tumours.Thromb Res. 2018 Apr;164 Suppl 1:S136-S142. doi: 10.1016/j.thromres.2018.01.021.
58	IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma.Nat Cell Biol. 2019 Aug;21(8):1003-1014. doi: 10.1038/s41556-019-0363-9. Epub 2019 Aug 1.
59	MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.Int J Cancer. 2010 Nov 1;127(9):2106-18. doi: 10.1002/ijc.25229.
60	Naringenin, a flavanone inhibits the proliferation of cerebrally implanted C6 glioma cells in rats.Chem Biol Interact. 2011 Jan 15;189(1-2):26-36. doi: 10.1016/j.cbi.2010.09.028. Epub 2010 Oct 7.
61	Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.Cancer Res. 2002 May 1;62(9):2468-73.
62	Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1).Environ Health Perspect. 2005 Jul;113(7):909-13. doi: 10.1289/ehp.7680.
63	Nogo receptor-vimentin interaction: a novel mechanism for the invasive activity of glioblastoma multiforme.Exp Mol Med. 2019 Oct 24;51(10):1-15. doi: 10.1038/s12276-019-0332-1.
64	SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency.Cell Host Microbe. 2017 May 10;21(5):569-579.e6. doi: 10.1016/j.chom.2017.04.011.
65	Measuring sulfatase expression and invasion in glioblastoma.Methods Mol Biol. 2015;1229:507-16. doi: 10.1007/978-1-4939-1714-3_39.
66	Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.J Neurooncol. 2018 Jun;138(2):241-250. doi: 10.1007/s11060-018-2799-3. Epub 2018 Feb 16.
67	Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity.PLoS One. 2019 Oct 10;14(10):e0223555. doi: 10.1371/journal.pone.0223555. eCollection 2019.
68	Evaluation of genetic alterations in cancer-related genes in lung and brain tumors from B6C3F1 mice exposed to 1,3-butadiene or chloroprene.Chem Biol Interact. 2007 Mar 20;166(1-3):112-20. doi: 10.1016/j.cbi.2006.04.015. Epub 2006 May 2.
69	Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.J Neurosurg. 2019 Feb 8;132(2):503-511. doi: 10.3171/2018.10.JNS182340.
70	Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-B signaling improves the efficacy of immunotherapy in a brain cancer model.Neurotherapeutics. 2012 Oct;9(4):827-43. doi: 10.1007/s13311-012-0144-7.
71	A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma.Cell Death Dis. 2018 Jul 10;9(7):767. doi: 10.1038/s41419-018-0799-z.
72	Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther. 2005 Sep;4(9):1293-302.
73	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.Neuro Oncol. 2014 Jan;16(2):173-8. doi: 10.1093/neuonc/not229. Epub 2013 Dec 4.
74	Hexokinase 2 (HK2), the tumor promoter in glioma, is downregulated by miR-218/Bmi1 pathway.PLoS One. 2017 Dec 8;12(12):e0189353. doi: 10.1371/journal.pone.0189353. eCollection 2017.
75	Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues.Int J Cancer. 2009 Mar 15;124(6):1258-62. doi: 10.1002/ijc.24023.
76	Use of the CRISPR-Cas9 system for genome editing in cultured Drosophila ovarian somatic cells.Methods. 2017 Aug 15;126:186-192. doi: 10.1016/j.ymeth.2017.05.021. Epub 2017 May 25.
77	L3MBTL2 regulates chromatin remodeling during spermatogenesis.Cell Death Differ. 2019 Nov;26(11):2194-2207. doi: 10.1038/s41418-019-0283-z. Epub 2019 Feb 13.
78	Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer.Oncol Lett. 2019 May;17(5):4640-4646. doi: 10.3892/ol.2019.10109. Epub 2019 Mar 5.
79	Glyco-genes change expression in cancer through aberrant methylation.Biochim Biophys Acta. 2016 Aug;1860(8):1776-85. doi: 10.1016/j.bbagen.2016.01.002. Epub 2016 Jan 12.
80	Molecular mechanisms of OLIG2 transcription factor in brain cancer.Oncotarget. 2016 Aug 16;7(33):53074-53101. doi: 10.18632/oncotarget.10628.
81	Novel functional association of serine palmitoyltransferase subunit 1-A peptide in sphingolipid metabolism with cytochrome P4501A1 transactivation and proliferative capacity of the human Glioma LN18 brain tumor cell line.Int J Environ Res Public Health. 2006 Sep;3(3):252-61. doi: 10.3390/ijerph2006030030.
82	Effects of Radiation Exposure on the Cost-Effectiveness of CT Angiography and Perfusion Imaging in Aneurysmal Subarachnoid Hemorrhage.AJNR Am J Neuroradiol. 2017 Mar;38(3):462-468. doi: 10.3174/ajnr.A5034. Epub 2017 Jan 12.
83	Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells.PLoS One. 2015 Feb 25;10(2):e0111532. doi: 10.1371/journal.pone.0111532. eCollection 2015.
84	Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer.J Clin Invest. 2019 Apr 8;129(5):1833-1835. doi: 10.1172/JCI128742. eCollection 2019 Apr 8.
85	Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2.Oncogene. 2001 Jan 18;20(3):336-45. doi: 10.1038/sj.onc.1204098.
86	A human IAP-family gene, apollon, expressed in human brain cancer cells.Biochem Biophys Res Commun. 1999 Nov 2;264(3):847-54. doi: 10.1006/bbrc.1999.1585.
87	Identification and characterization of a metastatic suppressor BRMS1L as a target gene of p53.Cancer Sci. 2017 Dec;108(12):2413-2421. doi: 10.1111/cas.13420. Epub 2017 Nov 6.
88	Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma.Int J Cancer. 2014 Mar 1;134(5):1112-22. doi: 10.1002/ijc.28440. Epub 2013 Sep 4.
89	Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer.Prostate. 2001 Sep 15;48(4):292-6. doi: 10.1002/pros.1109.
90	Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.Oncotarget. 2015 Jan 20;6(2):1157-70. doi: 10.18632/oncotarget.2708.
91	DAPK1 promoter hypermethylaiton in brain metastases and peripheral blood.Neoplasma. 2007;54(2):123-6.
92	Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis.Carcinogenesis. 2014 Apr;35(4):877-85. doi: 10.1093/carcin/bgt399. Epub 2013 Dec 4.
93	INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.BioDrugs. 2003;17(3):216-22. doi: 10.2165/00063030-200317030-00010.
94	FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.Oncogene. 2019 Sep;38(37):6445-6460. doi: 10.1038/s41388-019-0893-4. Epub 2019 Jul 19.
95	Somatic alterations in brain tumors.Oncol Rep. 2008 Jul;20(1):203-10.
96	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.Nature. 2017 Sep 28;549(7673):533-537. doi: 10.1038/nature24014. Epub 2017 Sep 20.
97	NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.Breast Cancer Res Treat. 2018 Nov;172(2):469-485. doi: 10.1007/s10549-018-4905-9. Epub 2018 Aug 20.
98	OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells.Int J Cancer. 2012 Jul 15;131(2):E21-32. doi: 10.1002/ijc.26474. Epub 2011 Nov 8.
99	Plasmacytoid dendritic cell in immunity and cancer.J Neuroimmunol. 2018 Sep 15;322:63-73. doi: 10.1016/j.jneuroim.2018.06.012. Epub 2018 Jun 26.
100	c-Myc regulates the coordinated transcription of brain disease-related PDCD10-SERPINI1 bidirectional gene pair.Mol Cell Neurosci. 2009 Sep;42(1):23-32. doi: 10.1016/j.mcn.2009.05.001. Epub 2009 May 13.
101	Enhanced pyruvate dehydrogenase activity improves cardiac outcomes in a murine model of cardiac arrest.PLoS One. 2017 Sep 21;12(9):e0185046. doi: 10.1371/journal.pone.0185046. eCollection 2017.
102	PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1/WDR5 complexes. Lab Invest. 2018 Dec;98(12):1627-1641. doi: 10.1038/s41374-018-0106-8. Epub 2018 Aug 8.
103	Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome.Mol Cancer. 2005 Feb 3;4(1):9. doi: 10.1186/1476-4598-4-9.
104	Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression.Mol Cell Biol. 2011 Mar;31(6):1225-39. doi: 10.1128/MCB.00607-10. Epub 2011 Jan 18.
105	Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway.FEBS Lett. 2013 Dec 11;587(24):3892-7. doi: 10.1016/j.febslet.2013.09.029. Epub 2013 Oct 11.
106	Rb family proteins in gastric cancer (review).Oncol Rep. 2010 Dec;24(6):1411-8. doi: 10.3892/or_00001000.
107	Implementation of a High-Throughput Pilot Screen in Peptide Hydrogel-Based Three-Dimensional Cell Cultures.SLAS Discov. 2019 Aug;24(7):714-723. doi: 10.1177/2472555219844570. Epub 2019 Apr 30.
108	Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.Dis Model Mech. 2018 Jun 15;11(6):dmm034124. doi: 10.1242/dmm.034124.
109	Lentiviral vector mediated delivery of RHBDD1 shRNA down regulated the proliferation of human glioblastoma cells.Technol Cancer Res Treat. 2014 Feb;13(1):87-93. doi: 10.7785/tcrt.2012.500362. Epub 2013 Jul 23.
110	Knockdown of ribosomal protein S15A induces human glioblastoma cell apoptosis.World J Surg Oncol. 2016 Apr 29;14:129. doi: 10.1186/s12957-016-0891-8.
111	Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):370-375. doi: 10.1073/pnas.1616100114. Epub 2016 Dec 23.
112	The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition.J Biol Chem. 2013 Sep 20;288(38):27680-27691. doi: 10.1074/jbc.M113.482349. Epub 2013 Aug 8.
113	Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells.Cells. 2019 Aug 1;8(8):808. doi: 10.3390/cells8080808.
114	Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray.J Allergy Clin Immunol. 2004 Oct;114(4):783-90. doi: 10.1016/j.jaci.2004.04.052.
115	Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis.BMC Genomics. 2011 Oct 14;12:505. doi: 10.1186/1471-2164-12-505.
116	TMEFF1 and brain tumors.Oncogene. 2003 May 8;22(18):2723-7. doi: 10.1038/sj.onc.1206351.
117	Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.
118	Cytoplasmic TRADD confers a worse prognosis in glioblastoma.Neoplasia. 2013 Aug;15(8):888-97. doi: 10.1593/neo.13608.